Page 1123

Category Archives: Cardiomyopathies

Heart patients dont need to panic: Doc – The Tribune India

Posted: March 18, 2020 at 11:41 am

Chandigarh, March 15 Heart patients dont need to panic over Covid-19. Continue reading

Posted in Cardiomyopathies | Comments Off on Heart patients dont need to panic: Doc – The Tribune India

Cell Culture Protein Surface Coating Market Analysis On Trends & Need 2025 – 3rd Watch News

Posted: at 11:41 am

Global Cell Culture Protein Surface Coating Market: Snapshot The global market for cell culture protein surface coatings is slated to expand at a highly promising pace in the next few years, thanks to the vast rise in investments by governments and market players in stem cell research and development activities. Cell culturing is a method used for growing artificial living cells outside the natural environment, under controlled physical conditions Continue reading

Posted in Cardiomyopathies | Comments Off on Cell Culture Protein Surface Coating Market Analysis On Trends & Need 2025 – 3rd Watch News

Stealth BioTherapeutics to Present at 40th Annual Cowen Health Care Conference – PRNewswire

Posted: February 27, 2020 at 8:48 pm

BOSTON, Feb. 27, 2020 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at the 40th Annual Cowen Health Care Conference in Boston, MA on Wednesday, March 4 at 10:40 am ET. A live audio webcast of the event will be available on the Investors & News section of Stealth's website athttps://investor.stealthbt.com/ Continue reading

Posted in Cardiomyopathies | Comments Off on Stealth BioTherapeutics to Present at 40th Annual Cowen Health Care Conference – PRNewswire

Cytokinetics to Announce Fourth Quarter Results on March 3, 2020 – Yahoo Finance

Posted: February 25, 2020 at 9:43 am

SOUTH SAN FRANCISCO, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (CYTK) today announced that it is scheduled to report fourth quarter results on March 3, 2020 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the companys outlook for the future. Continue reading

Posted in Cardiomyopathies | Comments Off on Cytokinetics to Announce Fourth Quarter Results on March 3, 2020 – Yahoo Finance

Cytokinetics Announces Publication Relating to Design of GALACTIC-HF, a Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure -…

Posted: February 9, 2020 at 4:48 pm

SOUTH SAN FRANCISCO, Calif., Feb. Continue reading

Posted in Cardiomyopathies | Comments Off on Cytokinetics Announces Publication Relating to Design of GALACTIC-HF, a Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure -…

Atrial fibrillation in athletes – CMAJ

Posted: January 13, 2020 at 6:48 pm

Too much exercise can cause atrial fibrillation Large observational studies have shown that a sedentary lifestyle increases the risk of atrial fibrillation fivefold.1,2 However, high-intensity aerobic exercise, especially for men, also increases the risk of atrial fibrillation at a threshold of more than 15002000 lifetime hours.3 Evidence is less clear for women.3 In the majority of athletes, atrial fibrillation is paroxysmal and symptomatic.2,3 High-intensity aerobic exercise causes increased hemodynamic stress and generates free radicals.4 The atria appear to be particularly susceptible, with resultant dilatation, chronic inflammation and fibrosis.24 Autonomic modulation also plays a role, and athletes commonly describe triggers that are vagally (sleep, meals) or adrenergically (exercise) mediated.2,3 It is important not to miss conditions associated with atrial fibrillation, including cardiomyopathies, channelopathies, pre-excitation, hyperthyroidism and alcohol or drug misuse.2,3 Energy supplements and performance enhancers should also be considered.2,3 Data on stroke risk among athletes are limited, but the use of thromboembolic risk scores (CHADS-65) is recommended.2,3,5 In nonrandomized studies, detraining has been shown to reduce atrial fibrillation, although athletes are often not willing to do this.2 Anti-arrhythmic medications are limited by bradycardia, impaired performance, long-term adverse effects and risk of ventricular arrhythmias during exercise.2,3 High-impact sports are a contraindication to anticoagulation.2,3 Data remain limited to small, nonrandomized studies, but ablation is often the preferred option for symptomatic athletes.2,3 Despite the distinct pathophysiology between symptomatic athletes and nonathletes, success rates appear similar to those of nonathletes: about 60% for the first procedure and > 80% for the second.2,3 Athletes not meeting CHADS-65 criteria must be informed of the need for anticoagulation for at least 2 months owing to the prothrombotic effect of catheter ablation.2,5 Continue reading

Posted in Cardiomyopathies | Comments Off on Atrial fibrillation in athletes – CMAJ

PET tracer can help fight heart attacks earlier in the process – Health Imaging

Posted: January 12, 2020 at 10:45 am

That animal cohort underwent a procedure to permanently close off a specific portion of the coronary artery, called ligation, while another four rats were imaged with the same radiotracer, but did not undergo the surgery. Continue reading

Posted in Cardiomyopathies | Comments Off on PET tracer can help fight heart attacks earlier in the process – Health Imaging

New PET tracer provides insight on cardiac failure risk after heart attack – DOTmed HealthCare Business News

Posted: at 10:45 am

A new PET radiotracer has shown promise for its ability to image fibroblast activity following a heart attack, say researchers in Germany. The team has gained greater insight into the recovery process of hearts that have undergone myocardial infarction, with the use of 68Ga-FAPI-04 PET, a radiopharmaceutical that can target fibroblast activation prior to it causing permanent damage. Its application enables clinicians to identify a window of time in which cardiac fibrosis, which can contribute to heart failure, can be prevented and the course of the disease altered Continue reading

Posted in Cardiomyopathies | Comments Off on New PET tracer provides insight on cardiac failure risk after heart attack – DOTmed HealthCare Business News

Cell Culture Protein Surface Coating Market Competitive Environment and Higher Growth Rate with Forecast to 2025 – Filmi Baba

Posted: January 4, 2020 at 9:44 pm

Global Cell Culture Protein Surface Coating Market: Snapshot The global market for cell culture protein surface coatings is slated to expand at a highly promising pace in the next few years, thanks to the vast rise in investments by governments and market players in stem cell research and development activities. Cell culturing is a method used for growing artificial living cells outside the natural environment, under controlled physical conditions. These cells are used to develop model systems for study and research of cellular structures as well as for drug discovery and genetic engineering. Continue reading

Posted in Cardiomyopathies | Comments Off on Cell Culture Protein Surface Coating Market Competitive Environment and Higher Growth Rate with Forecast to 2025 – Filmi Baba

Cytokinetics Announces New Results Presented at the International Symposium on ALS/MNDSubgroup Analyses of FORTITUDE-ALS on Effects of Reldesemtiv…

Posted: December 8, 2019 at 7:47 pm

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Inc.(Nasdaq: CYTK) today announced that new results were presented at the 30th International Symposium on ALS/MND in Perth, Australia, including additional analyses from FORTITUDE-ALS (Functional Outcomes in a Randomized Trial of Investigational Treatment with CK-2127107 to Understand Decline in Endpoints in ALS), the Phase 2 clinical trial of reldesemtiv in patients with amyotrophic lateral sclerosis (ALS). Among the post-hoc analyses presented were results of subgroup analyses describing the effect of reldesemtiv with and without use of Radicava (edaravone) and/or Rilutek (riluzole) and the interaction between quality of life and depression in the placebo group. Continue reading

Posted in Cardiomyopathies | Comments Off on Cytokinetics Announces New Results Presented at the International Symposium on ALS/MNDSubgroup Analyses of FORTITUDE-ALS on Effects of Reldesemtiv…

Page 1123